 Cerus provided 2022 product revenues guidance of a record 157 to 164 million, after delivery of better than expected 2021 product revenues of 130.9 Million 42 higher than 2020 product revenues. U.S.blood centers increased purchases of Cerus INTERCEPT platelet kits to comply with FDA order effective Oct.1. 